RxDoctor Payments Data

Jennifer Leiting, APRN

Family · Benkelman, NENPI 1407394935

Payments from drug & device makers

$793in general payments, 2019–2025

Across 34 payments — averaging $23.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$124
  • Medtronic$98
  • Boston Scientific$96
  • SPR Therapeutics, Inc$75
  • Protega Pharmaceutials Inc$64
  • Vertex$61
  • plus $275 from 8 others

What the payments were for

  • Food & beverage$793100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott6$124
Medtronic3$98
Boston Scientific2$96
SPR Therapeutics, Inc2$75
Protega Pharmaceutials Inc3$64
Vertex3$61
Si-bone, Inc.3$53
AbbVie3$53
Vertos Medical, Inc.2$49
Saluda Medical Americas, Inc.3$45
Lundbeck LLC1$22
Pfizer1$20
Tonix Medicines, Inc.1$20
Mylan Specialty L.p.1$12

How this compares

$793 in reported general payments places this provider in the 70th percentile of 809 family providers in Nebraska.

See all family providers in Nebraska

Medicare billing

Part B allowed, 2024
$43,533
Medicare patients
236
Services billed
558

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen399$14,628
Nurtec OdtRimegepant Sulfate14$14,294
LinzessLinaclotide14$7,644
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen179$5,136
Gabapentin325$4,702
Pregabalin117$3,089
Tramadol Hcl217$3,030
Morphine Sulfate ErMorphine Sulfate100$2,169
Tizanidine Hcl131$1,804
Cyclobenzaprine Hcl135$1,791
Buprenorphine11$1,676
Celecoxib91$1,653
Lidocaine23$1,414
Oxycodone Hcl59$986
Ropinirole Hcl43$814

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$20$14,29414 claims
AbbVieLinzess$53$7,64414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 809 family providers in Nebraska.

Other family in Benkelman

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →